LON:ABZA

Abzena Competitors

Add
Compare
Today's Range N/A
50-Day Range
15.75
MA: GBX 15.75
15.75
52-Week Range N/A
Volume100 shs
Average Volume220,500 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Abzena (LON:ABZA) Vs. GNS, ABC, BTG, PRTC, OXB, and ERGO

Should you be buying ABZA stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Abzena, including Genus (GNS), Abcam (ABC), BTG (BTG), PureTech Health (PRTC), Oxford Biomedica (OXB), and Ergomed (ERGO).

Abzena (LON:ABZA) and Genus (LON:GNS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Abzena and Genus' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbzenaN/AN/AN/AN/AN/A
Genus£566.40 million5.94N/AGBX 73.6069.97

Analyst Ratings

This is a breakdown of recent ratings and target prices for Abzena and Genus, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abzena0000N/A
Genus01102.50

Genus has a consensus price target of GBX 4,760, suggesting a potential downside of 7.57%.

Profitability

This table compares Abzena and Genus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbzenaN/AN/AN/A
GenusN/AN/AN/A

Summary

Genus beats Abzena on 2 of the 2 factors compared between the two stocks.

Abzena (LON:ABZA) and Abcam (LON:ABC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Abzena and Abcam's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbzenaN/AN/AN/AN/AN/A
Abcam£269.30 million12.14N/AGBX (0.90)-1,602.22

Analyst Ratings

This is a breakdown of recent ratings and target prices for Abzena and Abcam, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abzena0000N/A
Abcam05102.17

Abcam has a consensus price target of GBX 1,378.33, suggesting a potential downside of 4.42%.

Profitability

This table compares Abzena and Abcam's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbzenaN/AN/AN/A
AbcamN/AN/AN/A

Summary

Abcam beats Abzena on 2 of the 2 factors compared between the two stocks.

Abzena (LON:ABZA) and BTG (LON:BTG) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Abzena and BTG's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbzenaN/AN/AN/AN/AN/A
BTG£914.10 million3.57N/AGBX 28.5029.47

Analyst Ratings

This is a breakdown of recent ratings and target prices for Abzena and BTG, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abzena0000N/A
BTG0000N/A

Profitability

This table compares Abzena and BTG's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbzenaN/AN/AN/A
BTGN/AN/AN/A

Summary

BTG beats Abzena on 1 of the 1 factors compared between the two stocks.

Abzena (LON:ABZA) and PureTech Health (LON:PRTC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Abzena and PureTech Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abzena0000N/A
PureTech Health00403.00

PureTech Health has a consensus price target of GBX 481.25, suggesting a potential upside of 15.69%.

Profitability

This table compares Abzena and PureTech Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbzenaN/AN/AN/A
PureTech HealthN/AN/AN/A

Earnings and Valuation

This table compares Abzena and PureTech Health's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbzenaN/AN/AN/AN/AN/A
PureTech Health£12.26 million96.98N/AGBX 115.503.60

Summary

PureTech Health beats Abzena on 2 of the 2 factors compared between the two stocks.

Oxford Biomedica (LON:OXB) and Abzena (LON:ABZA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Oxford Biomedica and Abzena, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oxford Biomedica01202.67
Abzena0000N/A

Oxford Biomedica currently has a consensus target price of GBX 926.67, suggesting a potential downside of 7.89%.

Profitability

This table compares Oxford Biomedica and Abzena's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oxford BiomedicaN/AN/AN/A
AbzenaN/AN/AN/A

Earnings & Valuation

This table compares Oxford Biomedica and Abzena's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Biomedica£65.94 million12.57N/AGBX (16.40)-61.34
AbzenaN/AN/AN/AN/AN/A

Summary

Oxford Biomedica beats Abzena on 2 of the 2 factors compared between the two stocks.

Ergomed (LON:ERGO) and Abzena (LON:ABZA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Ergomed and Abzena, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ergomed0000N/A
Abzena0000N/A

Profitability

This table compares Ergomed and Abzena's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ErgomedN/AN/AN/A
AbzenaN/AN/AN/A

Earnings & Valuation

This table compares Ergomed and Abzena's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ergomed£86.39 million6.18N/AGBX 19.2057.03
AbzenaN/AN/AN/AN/AN/A

Summary

Ergomed beats Abzena on 1 of the 1 factors compared between the two stocks.


Abzena Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Genus logo
GNS
Genus
1.3$5,150.00flat£3.36 billion£566.40 million69.97News Coverage
Abcam logo
ABC
Abcam
0.5$1,442.00flat£3.27 billion£269.30 million-1,602.22News Coverage
Gap Up
BTG logo
BTG
BTG
0.7$840.00flat£3.26 billion£914.10 million29.47
PureTech Health logo
PRTC
PureTech Health
1.5$416.00flat£1.19 billion£12.26 million3.60Upcoming Earnings
Oxford Biomedica logo
OXB
Oxford Biomedica
0.8$1,006.00flat£828.99 million£65.94 million-61.34Upcoming Earnings
Analyst Report
Ergomed logo
ERGO
Ergomed
0.6$1,095.00flat£533.81 million£86.39 million57.03
Silence Therapeutics logo
SLN
Silence Therapeutics
0.9$539.00flat£481.86 million£5.48 million-13.54Gap Down
Synairgen logo
SNG
Synairgen
0.4$156.00flat£311.87 million£79,000.00-30.59News Coverage
NCYT
Novacyt
0.6$421.40flat£297.62 million£92.07 million6.00High Trading Volume
News Coverage
Gap Down
ORPH
Open Orphan
0.0$42.95flat£287.51 million£10.57 million-13.42High Trading Volume
News Coverage
Gap Up
ARIX
Arix Bioscience
0.8$190.00flat£256.40 million£135.77 million2.14High Trading Volume
Bioventix logo
BVXP
Bioventix
0.8$4,145.00flat£215.91 million£10.38 million31.59
DDDD
4D pharma
0.6$118.60flat£209.41 million£690,000.00-4.44
Tiziana Life Sciences logo
TILS
Tiziana Life Sciences
0.4$94.50flat£190.72 millionN/A-17.18
Scancell logo
SCLP
Scancell
0.6$22.90flat£186.69 millionN/A-16.36
Redx Pharma logo
REDX
Redx Pharma
0.6$67.50flat£184.87 million£5.69 million-12.50
Faron Pharmaceuticals Oy logo
FARN
Faron Pharmaceuticals Oy
0.6$347.50flat£175.20 million£2.50 million-7.97Gap Down
ANIC
Agronomics
0.5$29.00flat£145.55 million£1.05 million-145.00Gap Down
Mereo BioPharma Group plc (MPH.L) logo
MPH
Mereo BioPharma Group plc (MPH.L)
0.6N/AN/A£138.87 millionN/A-0.21Gap Up
VSN
Verseon
0.5N/AN/A£127.41 millionN/A-5.17Gap Down
Circassia Group logo
CIR
Circassia Group
0.9$29.00flat£121.12 million£23.90 million-3.30Insider Buying
Gap Down
Verona Pharma plc (VRP.L) logo
VRP
Verona Pharma plc (VRP.L)
0.5$25.99flat£107.74 millionN/A-0.79High Trading Volume
Destiny Pharma logo
DEST
Destiny Pharma
0.5$170.00flat£101.72 million£305,906.00-14.78Gap Up
SBTX
SkinBioTherapeutics
0.4$60.50flat£94.85 millionN/A-60.50News Coverage
Gap Up
C4XD
C4X Discovery
0.6$40.00flat£90.54 million£7.06 million-4.94
ETX
e-therapeutics
0.4$20.70flat£87.10 million£305,000.00-20.70
OBD
Oxford BioDynamics
0.5$91.00flat£84.23 million£456,000.00-19.36News Coverage
ReNeuron Group logo
RENE
ReNeuron Group
0.6$133.00flat£75.62 million£112,000.00-2.90Gap Up
OKYO
OKYO Pharma
0.5$7.65flat£51.47 millionN/A-76.50Gap Up
Tissue Regenix Group logo
TRX
Tissue Regenix Group
0.5$0.67flat£47.12 million£13.05 million-1.68Gap Down
OptiBiotix Health logo
OPTI
OptiBiotix Health
0.4$52.00flat£45.73 million£687,584.00-22.61Gap Up
HVO
Hvivo
0.5$52.53flat£43.95 million£12.09 million-2.63
4BB
4basebio UK Societas
0.3$335.00flat£41.26 millionN/A0.00
FAB
Fusion Antibodies
0.5$151.00flat£39.18 million£4.05 million-50.33High Trading Volume
News Coverage
RUA
Rua Life Sciences
0.0$155.00flat£34.39 million£835,000.00-18.90Gap Up
HEMO
Hemogenyx Pharmaceuticals
0.4$7.50flat£34.09 millionN/A-18.75
IXICO logo
IXI
IXICO
1.0$70.50flat£33.82 million£9.53 million35.25Gap Up
COS
Collagen Solutions plc (COS.L)
0.6N/AN/A£28.43 million£4.01 million-8.28
ImmuPharma logo
IMM
ImmuPharma
0.6$10.06flat£25.16 million£128,395.00-3.35
AOR
AorTech International
0.5$123.50flat£21.85 million£539,000.00-33.38
Midatech Pharma logo
MTPH
Midatech Pharma
0.7$31.00flat£19.65 million£390,000.00-0.33News Coverage
Gap Up
NFX
Nuformix
0.5$2.55flat£15.09 million£195,550.00-12.75Gap Down
ValiRx logo
VAL
ValiRx
0.7$20.75flat£13.50 millionN/A-1.15News Coverage
RLM
Realm Therapeutics
0.6N/AN/A£13.41 million£501,919.00-0.66
OVB
Ovoca Bio
0.7$11.50flat£10.17 millionN/A-2.30Gap Up
NSCI
NetScientific
0.5$66.50flat£9.99 million£394,000.00-22.93Gap Up
Horizon Discovery Group plc (HZD.L) logo
HZD
Horizon Discovery Group plc (HZD.L)
1.3$4.97flat£8.16 million£54.63 million-0.90
PYC
Physiomics
0.4$7.05flat£6.86 million£884,649.00-70.50Gap Up
Motif Bio logo
MTFB
Motif Bio
0.6N/AN/A£3.28 millionN/A-0.18
SALV
SalvaRx Group
0.8N/AN/A£1.65 million£64.50 million0.03Gap Down
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.